The differences in immunogenicity of TP53 mutated endometrial-, high-grade serous ovarian- and triple negative breast carcinomas

被引：0
|
作者：
Zeimet, A. G. [1 ]
Leitner, K. [1 ]
Hackl, H. [2 ]
Fiegl, H. [1 ]
Feroz, B. [1 ]
Marth, C. [1 ]
Steger, K. [1 ]
机构：
[1] Med Univ Innsbruck, Gynecol & Obstet, Innsbruck, Austria
[2] Med Univ Innsbruck, Inst Bioinformat, Innsbruck, Austria
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.08.2152
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
792P
引用
收藏
页码：S591 / S591
页数：1
相关论文
共 50 条
  • [21] Most High Grade Serous Carcinomas Arising in Low Grade Serous Carcinomas Do Not Show Evidence of TP53 or BRAF Mutations
    Zarei, Shabnam
    Kerr, Sarah E.
    Wang, Yan
    Jenkins, Sarah M.
    Bell, Debra A.
    MODERN PATHOLOGY, 2016, 29 : 315A - 315A
  • [22] Most High Grade Serous Carcinomas Arising in Low Grade Serous Carcinomas Do Not Show Evidence of TP53 or BRAF Mutations
    Zarei, Shabnam
    Kerr, Sarah E.
    Wang, Yan
    Jenkins, Sarah M.
    Bell, Debra A.
    LABORATORY INVESTIGATION, 2016, 96 : 315A - 315A
  • [23] Molecular Alterations of TP53 are a Defining Feature of Ovarian High-Grade Serous Carcinoma: A Rereview of Cases Lacking TP53 Mutations in The Cancer Genome Atlas Ovarian Study
    Vang, Russell
    Levine, Douglas A.
    Soslow, Robert A.
    Zaloudek, Charles
    Shih, Ie-Ming
    Kurman, Robert J.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, 2016, 35 (01) : 48 - 55
  • [24] The diagnostic utility of TP53 and CDKN2A to distinguish ovarian high-grade serous carcinoma from low-grade serous ovarian tumors
    Altman, Alon D.
    Nelson, Gregg S.
    Ghatage, Prafull
    McIntyre, John B.
    Capper, David
    Chu, Pamela
    Nation, Jill G.
    Karnezis, Anthony N.
    Han, Guangming
    Kalloger, Steve E.
    Koebel, Martin
    MODERN PATHOLOGY, 2013, 26 (09) : 1255 - 1263
  • [25] Spectrum of TP53 Mutations in BRCA1/2 Associated High-Grade Serous Ovarian Cancer
    Boyarskikh, Ulyana A.
    Gulyaeva, L. F.
    Avdalyan, A. M.
    Kechin, A. A.
    Khrapov, E. A.
    Lazareva, D. G.
    Kushlinskii, N. E.
    Melkonyan, A.
    Arakelyan, A.
    Filipenko, Maxim Leonidovich
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [26] The effect of germline polymorphisms on somatic hotspot mutations in TP53 for the treatment of high-grade serous ovarian carcinoma
    De Souza, Cristabelle Madona N.
    CANCER RESEARCH, 2018, 78 (13)
  • [27] Similar protein expression profiles of ovarian and endometrial high-grade serous carcinomas
    Kosuke Hiramatsu
    Kiyoshi Yoshino
    Satoshi Serada
    Kosuke Yoshihara
    Yumiko Hori
    Minoru Fujimoto
    Shinya Matsuzaki
    Tomomi Egawa-Takata
    Eiji Kobayashi
    Yutaka Ueda
    Eiichi Morii
    Takayuki Enomoto
    Tetsuji Naka
    Tadashi Kimura
    British Journal of Cancer, 2016, 114 : 554 - 561
  • [28] Similar protein expression profiles of ovarian and endometrial high-grade serous carcinomas
    Hiramatsu, Kosuke
    Yoshino, Kiyoshi
    Serada, Satoshi
    Yoshihara, Kosuke
    Hori, Yumiko
    Fujimoto, Minoru
    Matsuzaki, Shinya
    Egawa-Takata, Tomomi
    Kobayashi, Eiji
    Ueda, Yutaka
    Morii, Eiichi
    Enomoto, Takayuki
    Naka, Tetsuji
    Kimura, Tadashi
    BRITISH JOURNAL OF CANCER, 2016, 114 (05) : 554 - 561
  • [29] High-grade TP53-mutated endometrial carcinomas have decreased NRF2 antioxidant activity
    Beinse, Guillaume
    Just, Pierre-Alexandre
    Rance, Bastien
    Izac, Brigitte
    Letourneur, Franck
    Saidu, Nathaniel Edward
    Chouzenoux, Sandrine
    Goldwasser, Francois
    Pasmant, Eric
    Batteux, Frederic
    Borghese, Bruno
    Leroy, Karen
    Alexandre, Jerome
    CANCER RESEARCH, 2018, 78 (13)
  • [30] Immunohistochemistry predicts presence and type of TP53 mutation in high-grade serous carcinoma
    Koebel, Martin
    Piskorz, Anna
    Liu, Shuhong
    Brenton, James D.
    CANCER RESEARCH, 2014, 74 (19)
12345